Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Invivyd, Inc. IVVD

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$53.4M
▲ 110.5% YoY
$-52.5M
$-58.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The company aims to develop mAbs that could be used in prevention or treatment of serious viral infectious diseases, starting with COVID-19 and expanding into other high-need indications, such as respiratory syncytial virus and measles. As of February 1, 2026, the company had 122 employees, all of which were full-time employees. Approximately 16 of the company's employees have Ph.D. or M.D. degrees and 35 of its employees are engaged in research and development activities. The company operates as a hybrid company with employees working at its corporate headquarters in New Haven, Connecticut, its laboratory in Newton, Massachusetts and remotely.

Written from the business description in Invivyd, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth

USD 53.4M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 53.4 · Net income -52.5
20M40M-100M-200M
202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−98 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -104.0% · Net -98.2%
-200%-400%-600%
202020222025
ROE
FY2025 · ROE -34.0%
-50%-100%
202020222025
Three returns, three denominators.

Each USD of equity lost 34 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -58.3
-100M-200M
202020222025
Net buybacks $M Dividends $M
FY2024 · Dividends · · Net buybacks -0.2
-150M-300M
2021202220232024

Total assetsUSD 276.9M
EquityUSD 241.5M
CashUSD 226.7M
Current ratio7.24×

Equity funds 87% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IVVD, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.10.00.0◌◌◌
Operating income $B−0.1−0.2−0.2−0.2−0.2◌
EBITDA $B◌◌−0.2−0.2−0.2◌
Income tax $B0.00.00.00.00.0◌
Net income $B−0.1−0.2−0.2−0.2−0.2−0.0
Free cash flow $B−0.1−0.2−0.2−0.2−0.2◌
EPS, diluted $−0.30−1.43−1.81−2.23−5.32◌
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−34.0−138.7−74.5−52.8——
Shares out B0.280.120.110.110.110.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 23 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 14 checks were skipped: EPS is not tagged before 2021.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image